Most Read Articles
Elaine Soliven, 16 Oct 2018
The use of degludec in insulin-naïve patients with type 2 diabetes (T2D) appears to reduce HbA1c levels with a lower risk of hypoglycaemia, based on real-world data from the CONFIRM* trial presented at EASD 2018.
Audrey Abella, 30 Apr 2018
The selective β3-adrenoreceptor (AR) agonist vibegron showed superior efficacy over placebo for overactive bladder (OAB) treatment and was generally well-tolerated, according to a Japanese study presented at EAU 2018.

Roshini Claire Anthony, 17 Jul 2019

A combination of tocilizumab and methotrexate reduced disease activity at 2 years compared with methotrexate plus prednisone in patients with early rheumatoid arthritis (RA), an effect not demonstrated with tocilizumab monotherapy.

Pearl Toh, 24 Dec 2018
The anticholinergic agent oxybutynin significantly reduces the intensity and frequency of hot flushes among women in whom hormone replacement therapy was contraindicated such as breast cancer survivors, according to the ACCRU study SC-1603 presented at SABCS 2018.

Intrauterine exposure to oral contraceptives marginally affects pubertal timing

08 Sep 2019

Children exposed to oral contraceptives (OCs) early in pregnancy tend to start puberty and achieve some pubertal milestones at an earlier age, although the magnitude of effect is small and imprecise, a study has found.

The analysis included 15,800 children born during 2000–2003 into the Danish National Birth Cohort, grouped according to maternal use of combined OC pills or progestin-only pills reported around gestational week 17: no exposure (reference; n=11,828), exposure 4 months before conception (n=3,518) and exposure in early pregnancy (n=454). Children self-assessed pubertal status by completing web-based questionnaires from 11 years and biannually throughout puberty.

Intrauterine exposure to OCs showed a tendency toward slightly earlier mean age of achieving some individual pubertal milestones and overall pubertal timing. Specific milestones included voice break (months, −3.8; 95 percent CI, −6.5 to −1.0) and first ejaculation (months, −2.9, −5.9 to 0.1) in boys, and menarche (months, −1.9, −4.0 to 0.3) and Tanner breast stages in girls. The mean age difference for overall pubertal timing was −1.4 months (−3.3 to 0.4) in boys and −0.9 months (−2.7 to 1.0) in girls.

OC exposure prior to conception was not associated with pubertal timing. Furthermore, prepubertal body mass index did not exhibit a mediating effect.

Additional studies are needed, particularly those that that can distinguish between formulations of OCs and timing of exposure in foetal life, owing to the study limitations and rarity of the exposure, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 16 Oct 2018
The use of degludec in insulin-naïve patients with type 2 diabetes (T2D) appears to reduce HbA1c levels with a lower risk of hypoglycaemia, based on real-world data from the CONFIRM* trial presented at EASD 2018.
Audrey Abella, 30 Apr 2018
The selective β3-adrenoreceptor (AR) agonist vibegron showed superior efficacy over placebo for overactive bladder (OAB) treatment and was generally well-tolerated, according to a Japanese study presented at EAU 2018.

Roshini Claire Anthony, 17 Jul 2019

A combination of tocilizumab and methotrexate reduced disease activity at 2 years compared with methotrexate plus prednisone in patients with early rheumatoid arthritis (RA), an effect not demonstrated with tocilizumab monotherapy.

Pearl Toh, 24 Dec 2018
The anticholinergic agent oxybutynin significantly reduces the intensity and frequency of hot flushes among women in whom hormone replacement therapy was contraindicated such as breast cancer survivors, according to the ACCRU study SC-1603 presented at SABCS 2018.